Your browser is no longer supported. Please, upgrade your browser.
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E465.86 EPS (ttm)0.18 Insider Own0.60% Shs Outstand90.75M Perf Week-0.08%
Market Cap7.65B Forward P/E31.46 EPS next Y2.68 Insider Trans-21.06% Shs Float89.55M Perf Month-4.16%
Income21.10M PEG- EPS next Q-0.76 Inst Own- Short Float5.19% Perf Quarter-15.26%
Sales451.20M P/S16.96 EPS this Y113.70% Inst Trans4.97% Short Ratio3.77 Perf Half Y-26.03%
Book/sh5.30 P/B15.91 EPS next Y328.80% ROA2.40% Target Price106.19 Perf Year-1.24%
Cash/sh7.17 P/C11.76 EPS next 5Y- ROE5.10% 52W Range64.72 - 126.98 Perf YTD18.08%
Dividend- P/FCF99.89 EPS past 5Y18.30% ROI4.20% 52W High-33.60% Beta1.95
Dividend %- Quick Ratio8.20 Sales past 5Y174.10% Gross Margin98.90% 52W Low30.28% ATR2.92
Employees585 Current Ratio8.40 Sales Q/Q39.20% Oper. Margin8.20% RSI (14)50.28 Volatility1.99% 3.42%
OptionableYes Debt/Eq0.00 EPS Q/Q142.90% Profit Margin4.70% Rel Volume0.55 Prev Close84.55
ShortableYes LT Debt/Eq0.81 EarningsFeb 05 AMC Payout0.00% Avg Volume1.23M Price84.32
Recom1.80 SMA20-3.17% SMA503.29% SMA200-15.28% Volume681,319 Change-0.27%
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Oct-04-16Resumed Leerink Partners Outperform $70
Jun-29-16Initiated H.C. Wainwright Buy $80
Oct-12-15Reiterated Leerink Partners Outperform $67 → $71
Oct-08-15Reiterated Piper Jaffray Overweight $86 → $96
Sep-16-15Reiterated Piper Jaffray Overweight $82 → $86
Aug-18-15Resumed Jefferies Buy
Feb-12-19 09:30AM  CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Feb-08-19 06:48AM  Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-06-19 09:20PM  Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 08:04PM  Neurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:35PM  Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates Zacks
05:37PM  Neurocrine: 4Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results PR Newswire
02:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
07:47AM  The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga
Jan-31-19 02:45PM  Here are Boston-area biotechs pursuing Parkinson's treatments American City Business Journals
Jan-29-19 01:42PM  Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today Motley Fool
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
07:00AM  Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinsons Disease and Friedreichs Ataxia GlobeNewswire
Jan-28-19 09:33AM  Will Neurocrine Biosciences Continue to Surge Higher? Zacks
Jan-25-19 07:45AM  Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-16-19 04:01PM  New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders PR Newswire
06:57AM  4 Defensive Stocks to Buy Amid Shutdown and Brexit Zacks
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch
04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results PR Newswire
Jan-14-19 08:00AM  Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences ACCESSWIRE
Jan-11-19 04:25PM  Biotech Stocks Are Enjoying Their Best-Ever Start to the Year Bloomberg
01:32PM  Is Neurocrine Biosciences, Inc.s (NASDAQ:NBIX) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 12:42PM  Neurocrine Gives Ingrezza Sales View, Updates on Pipeline Zacks +9.57%
07:15AM  Neurocrine Biosciences Is a Pharma Stock to Watch InvestorPlace
06:50AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology ACCESSWIRE
Jan-06-19 06:30PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones PR Newswire
10:56AM  Neurocrine Biosciences Looks Oversold GuruFocus.com
Jan-02-19 04:01PM  Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-31-18 07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool
Dec-14-18 08:37AM  Do Options Traders Know Something About Neurocrine Biosciences (NBIX) Stock We Don't? Zacks
Dec-13-18 06:55AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals ACCESSWIRE
Dec-12-18 04:35PM  Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today Motley Fool -13.91%
12:49PM  Why Neurocrine Biosciences Is Tanking Motley Fool
07:39AM  Neurocrine Biosciences says trial of Tourette syndrome treatment missed primary goal MarketWatch
07:30AM  Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome PR Newswire
Dec-09-18 03:31AM  Should You Buy Neurocrine Biosciences, Inc. (NBIX)? Insider Monkey
Nov-27-18 07:15AM  3 Top Biotech Stocks to Buy Right Now Motley Fool -6.70%
Nov-17-18 03:53PM  Edited Transcript of NBIX earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-18 09:04AM  Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5% Zacks
Nov-15-18 07:00AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Amarin ACCESSWIRE +6.48%
Nov-14-18 05:35PM  AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress PR Newswire -13.44%
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace
Nov-09-18 08:30AM  Report: Developing Opportunities within Louisiana-Pacific, Neurocrine Biosciences, Tahoe Resources, Loews, Quotient Technology, and Evolent Health Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-07-18 04:01PM  Neurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference PR Newswire
12:17PM  Does Neurocrine Biosciences Incs (NASDAQ:NBIX) Debt Level Pose A Problem? Simply Wall St.
Nov-05-18 05:15PM  Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates Zacks
04:11PM  Neurocrine: 3Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports Third Quarter 2018 Financial Results PR Newswire
07:00AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Exelixis ACCESSWIRE
Nov-02-18 11:41AM  Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO Zacks
Oct-31-18 10:25AM  Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-29-18 10:31AM  Neurocrine Biosciences (NBIX) Q3 Earnings Preview: What to Look Out For Zacks
Oct-23-18 04:01PM  Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress PR Newswire
Oct-15-18 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results PR Newswire
08:35AM  New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Tesaro and Neurocrine Biosciences ACCESSWIRE
Oct-10-18 04:54PM  Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Oct-09-18 04:01PM  Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders PR Newswire
Oct-08-18 11:51AM  AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis Zacks
Oct-05-18 05:13PM  AbbVie Receives Health Canada Approval of ORILISSA (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
09:30AM  UTHR vs. NBIX: Which Stock Is the Better Value Option? Zacks
Oct-01-18 04:01PM  Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders PR Newswire
Sep-30-18 03:30PM  Here's What Could Cause Neurocrine Biosciences Shares to Skyrocket Motley Fool
Sep-28-18 11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
Sep-10-18 04:10PM  A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others Benzinga
Sep-07-18 03:57PM  Stock Market Forecast: More Gains, More Volatility Investor's Business Daily
Sep-05-18 04:01PM  Neurocrine Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference PR Newswire
Aug-22-18 08:30AM  AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids PR Newswire
Aug-20-18 06:03PM  Edited Transcript of NBIX earnings conference call or presentation 31-Jul-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-15-18 04:01PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders PR Newswire
Aug-13-18 07:50AM  Report: Developing Opportunities within Energy Recovery, Lamb Weston, Neurocrine Biosciences, Pioneer Natural Resources, Meritor, and Ophthotech Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-07-18 11:07AM  4 Reasons Behind Stifel's Neurocrine Bull Thesis Benzinga
Aug-02-18 08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences ACCESSWIRE
Aug-01-18 01:14PM  Here's Why Neurocrine Biosciences Stock Rose as Much as 14.3% Today Motley Fool +13.00%
11:40AM  Neurocrine stock rises 11% after Q2 revenue beat MarketWatch
Jul-31-18 04:28PM  Neurocrine: 2Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports Second Quarter 2018 Financial Results PR Newswire
02:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Jul-24-18 01:46PM  AbbVie prices new endometriosis drug at $10,000 a year Reuters
08:30AM  AbbVie Receives U.S. FDA Approval of ORILISSA (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis PR Newswire
Jul-10-18 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results PR Newswire
Jul-05-18 07:25AM  Free Technical Reports on Novavax and Three Additional Biotech Equities ACCESSWIRE
Jun-27-18 06:01AM  3 Biotech Stocks With Major Potential Catalysts in July Motley Fool
Jun-20-18 07:52AM  5 Stocks That Are Screaming Buys Right Now TheStreet.com
Jun-08-18 04:56PM  Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego PR Newswire
Jun-02-18 04:34PM  What You Must Know About Neurocrine Biosciences Incs (NASDAQ:NBIX) Financial Strength Simply Wall St.
May-22-18 07:00AM  Free Technical Insights on OPKO Health and Three Other Biotech Stocks ACCESSWIRE
May-14-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews New Research Emphasizes Economic Growth GlobeNewswire
May-09-18 04:01PM  Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference PR Newswire
06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 02:00PM  Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics PR Newswire
May-03-18 10:15AM  NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth Zacks Small Cap Research
May-02-18 04:14PM  Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting PR Newswire -5.11%
01:52PM  Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT Thomson Reuters StreetEvents
May-01-18 07:51AM  Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings Benzinga
Apr-30-18 04:21PM  Neurocrine: 1Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports First Quarter 2018 Financial Results PR Newswire
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bozigian Haig P.Chief Development OfficerFeb 06Sale83.5492076,859141,639Feb 08 05:06 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale83.5792076,88320,745Feb 08 05:06 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale83.5892076,89419,238Feb 08 05:11 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale84.234,096344,986417,597Feb 08 05:09 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale84.0353144,622120,065Feb 08 05:09 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale83.5279166,06319,646Feb 08 05:10 PM
Gano KyleChief Business Development OffFeb 06Sale83.5676263,67385,833Feb 08 05:07 PM
Gano KyleChief Business Development OffFeb 05Sale88.122,434214,48280,989Feb 06 06:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale88.194,489395,895410,185Feb 06 06:03 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale88.011,357119,42717,595Feb 06 05:59 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale88.091,225107,91117,482Feb 06 06:05 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale88.141,272112,11916,574Feb 06 06:06 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale88.141,350118,986138,244Feb 06 05:59 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale88.171,07094,338118,322Feb 06 06:04 PM
Gano KyleChief Business Development OffFeb 04Sale88.141,375121,18680,117Feb 06 06:03 PM
Bozigian Haig P.Chief Development OfficerFeb 04Sale88.101,375121,139137,372Feb 06 05:59 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 04Sale88.103,125275,321408,082Feb 06 06:03 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 04Sale88.121,375121,167117,066Feb 06 06:04 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale84.091,857156,1593,143Jan 10 04:47 PM
ABERNETHY MATTChief Financial OfficerDec 03Sale90.001,178106,0201,947Dec 06 05:54 PM
POPS RICHARD FDirectorNov 26Sale91.374,124376,79029,512Nov 27 06:58 PM
POPS RICHARD FDirectorNov 12Sale103.304,123425,89333,636Nov 13 06:18 PM
Bozigian Haig P.Chief Development OfficerNov 08Option Exercise8.6636,295314,147155,498Nov 13 04:15 PM
Bozigian Haig P.Chief Development OfficerNov 08Sale110.0036,2953,992,450135,997Nov 13 04:15 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 07Option Exercise15.453,30050,98518,618Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 07Option Exercise12.6229,399371,105151,043Nov 08 05:04 PM
Bozigian Haig P.Chief Development OfficerNov 07Sale110.1429,3993,238,132135,997Nov 08 05:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 07Sale110.003,300363,00015,318Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 06Option Exercise35.999,420339,026145,417Nov 08 05:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 06Option Exercise15.455,70088,06521,018Nov 08 05:03 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 06Sale110.025,700627,09615,318Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 06Sale110.109,4201,037,167135,997Nov 08 05:04 PM
LYONS GARY ADirectorNov 02Sale114.4115,0001,716,213245,697Nov 05 04:11 PM
POPS RICHARD FDirectorOct 29Sale107.135,500589,23737,759Oct 30 05:58 PM
Grigoriadis Dimitri E.Chief Research OfficerSep 04Option Exercise12.2132,749399,977115,691Sep 05 08:41 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 01Option Exercise19.5923,022451,001105,964Aug 03 04:07 PM
Gano KyleChief Business Development OffAug 01Option Exercise8.6628,266244,784107,008Aug 03 04:08 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 01Sale110.0023,0222,532,42082,942Aug 03 04:07 PM
Gano KyleChief Business Development OffAug 01Sale115.0028,2663,250,59078,742Aug 03 04:08 PM
GORMAN KEVIN CHARLESChief Executive OfficerJun 28Option Exercise9.2157,924533,416404,957Jun 29 07:32 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 20Option Exercise19.5923,000450,570105,942Jun 21 06:16 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 20Sale105.0023,0002,415,00082,942Jun 21 06:16 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 14Option Exercise19.592,78554,55885,727Jun 15 04:44 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 14Sale100.002,785278,50082,942Jun 15 04:44 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 13Option Exercise11.2884,178949,292146,905Jun 15 04:44 PM
LYONS GARY ADirectorJun 13Sale99.2415,0001,488,549260,697Jun 15 04:45 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 13Sale99.4684,1788,372,23882,942Jun 15 04:44 PM
SHERWIN STEPHEN ADirectorJun 11Sale98.4410,000984,42047,548Jun 13 12:34 PM
BENEVICH ERICChief Commercial OfficerJun 01Sale97.3412,3501,202,16416,690Jun 05 06:53 PM
Nevinny Corinne HDirectorMay 07Sale83.135,000415,62543,283May 09 06:12 PM
Nevinny Corinne HDirectorMay 02Option Exercise7.0515,000105,75049,603May 03 07:53 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 01Option Exercise5.76126,832730,552473,865May 03 07:39 PM
POPS RICHARD FDirectorMay 01Option Exercise7.0515,000105,75044,512May 03 07:42 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 01Sale80.75126,83210,241,735347,033May 03 07:39 PM
SHERWIN STEPHEN ADirectorApr 26Option Exercise7.0515,000105,75058,879Apr 30 04:03 PM
LYONS GARY ADirectorApr 03Option Exercise7.0515,000105,750277,066Apr 05 06:52 PM
Bozigian Haig P.Chief Development OfficerMar 05Option Exercise12.8775,873976,703197,471Mar 07 04:13 PM
Gano KyleChief Business Development OffMar 05Option Exercise8.6523,650204,573102,392Mar 07 04:16 PM
Lippoldt DarinChief Legal OfficerMar 05Option Exercise18.151,97935,91918,041Mar 07 04:18 PM
Lippoldt DarinChief Legal OfficerMar 05Sale88.471,979175,09016,062Mar 07 04:18 PM
Bozigian Haig P.Chief Development OfficerMar 05Sale90.0075,8736,828,570135,997Mar 07 04:13 PM
Gano KyleChief Business Development OffMar 05Sale90.0023,6502,128,50078,742Mar 07 04:16 PM